Pfs Partners, LLC Trevi Therapeutics, Inc. Transaction History
Pfs Partners, LLC
- $199 Billion
- Q2 2025
A detailed history of Pfs Partners, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Pfs Partners, LLC holds 79,000 shares of TRVI stock, worth $583,810. This represents 0.22% of its overall portfolio holdings.
Number of Shares
79,000
Previous 79,000
-0.0%
Holding current value
$583,810
Previous $497 Million
13.04%
% of portfolio
0.22%
Previous 0.26%
Shares
3 transactions
Others Institutions Holding TRVI
# of Institutions
147Shares Held
85.4MCall Options Held
1.51MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$84 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$75.8 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$33.5 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$28.4 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$25.8 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $431M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...